Results from a 108-week clinical trial
AUBAGIO® (teriflunomide) was studied in a 108-week clinical trial of more than 1,000 patients. In this trial, AUBAGIO 14 mg demonstrated a significant positive effect vs. placebo on 3 key measures of MS disease activity—relapses, disability progression, and MRI brain lesions.
AUBAGIO 7 mg demonstrated a significant positive effect vs. placebo on 2 of 3 key measures of MS disease activity—relapses and MRI brain lesions.
AUBAGIO 14 mg slows disability progression vs. placebo
In a clinical trial, patients taking AUBAGIO 14 mg were 30% less likely to have sustained disability progression vs. those on placebo. AUBAGIO 7 mg did not demonstrate a statistically significant effect on sustained disability progression.
Sustained disability progression is a measure of disability progression over time. This means walking and other basic activities may become more difficult. As noted, AUBAGIO 14 mg has been shown to slow disability progression.
8 out of 10 patients with MS did not experience sustained disability progression at week 108 with AUBAGIO 14 mg.
- 17.3%, 18.6%, and 23.7% of patients experienced sustained disability progression at week 108 with AUBAGIO 14 mg, AUBAGIO 7 mg, and placebo, respectively (AUBAGIO 7 mg did not achieve statistical significance).
AUBAGIO reduces relapses
In a clinical trial, patients taking AUBAGIO 14 mg or 7 mg showed a 31% reduction in MS relapses vs. those on placebo.
61% of patients had zero relapses over the course of the clinical trial with AUBAGIO 14 mg.
60.6%, 57.8%, and 49.3% of patients remained relapse-free at week 108 with AUBAGIO 14 mg, AUBAGIO 7 mg, and placebo, respectively.
Before taking AUBAGIO, talk with your healthcare provider if you have: liver or kidney problems; a fever or infection, or if you are unable to fight infections; numbness or tingling in your hands or feet that is different from your MS symptoms; diabetes; serious skin problems when taking other medicines; breathing problems; or high blood pressure.
Fewer new, active brain lesions with AUBAGIO
In a clinical trial, AUBAGIO 14 mg reduced the number of new, active brain lesions on MRI by 80% vs. placebo. AUBAGIO 7 mg reduced the number of new, active brain lesions by 57% vs. placebo.
64% of patients were free of new, active brain lesions at week 108 in a Phase III clinical trial with AUBAGIO 14 mg.